News FDA experts to vote on Spark's groundbreaking gene therapy Luxturna could be single life-changing injection
News Spark files revolutionary gene therapy with FDA Luxturna granted six-month priority review by FDA.
News Submission completed, Spark sets sight on first ever US gene... Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.
News Spark and Pfizer's haemophilia gene therapy gets European PR... Decision based on promising data from ongoing phase 1/2 trial.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News Spark’s gene therapy shows great promise in restoring sight Philadelphia-based company could be frontrunner in gene therapy
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
